发明名称 |
Therapy for complications of diabetes |
摘要 |
A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist. |
申请公布号 |
US8865650(B2) |
申请公布日期 |
2014.10.21 |
申请号 |
US201314079464 |
申请日期 |
2013.11.13 |
申请人 |
AbbVie Deutschland GmbH & Co. KG |
发明人 |
Roden Robert L.;Gorczynski Richard J.;Gerber Michael J. |
分类号 |
A61K45/06;A61K31/549;A61K31/505;A61K31/4025 |
主分类号 |
A61K45/06 |
代理机构 |
Neal, Gerber & Eisenberg LLP |
代理人 |
Neal, Gerber & Eisenberg LLP |
主权项 |
1. A method for treating diabetic nephropathy in a human subject in need of such treatment, said method comprising:
administering to the subject atrasentan or a salt thereof, and a dose of at least one angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker. |
地址 |
Wiesbaden DE |